Study assesses diagnostic accuracy of combining prostate health index and soluble e-cadherin for prostate cancer, suggesting enhanced detection capabilities.
Objective To assess the diagnostic value of combining prostate health index (PHI) and soluble epithelial cadherin (sE-cadherin) in prostate cancer (PCa) detection. Methods This study included 250 benign prostatic hyperplasia (BPH) and 250 PCa patients (2020–2024). PCa patients were categorized by disease stage (I-II:115; III-IV:135), bone metastasis (non-metastatic:171; metastatic:79), and Gleason score (≤8:136; >8:114). Serum sE-cadherin (ELISA), tPSA, fPSA, and p2PSA (chemiluminescence) were measured; PHI was calculated. ROC curves evaluated diagnostic performance. Results sE-cadherin, tPSA, p2PSA, and PHI levels were significantly higher in PCa vs. BPH (P<0.05), with further elevations in advanced stages, metastatic cases, and Gleason >8 (P<0.05). ROC analysis demonstrated AUCs of 0.719 (sE-cadherin), 0.761 (PHI), and 0.792 (combined), indicating superior diagnostic accuracy for the combination. Conclusion Combining sE-cadherin and PHI enhances PCa detection accuracy, correlating with disease severity, metastasis, and aggressiveness.
No takes yet. Share an insight, caveat, or question.
Ahamed et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: